Seragon names Tony Coles to board
This article was originally published in Scrip
Executive Summary
San Diego-based Seragon Pharmaceuticals, a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, has named N Anthony (Tony) Coles to its board of directors. Most recently, Dr Coles was president, chief executive officer and chair of the board of Onyx Pharmaceuticals, a global biopharmaceutical company acquired by Amgen in October 2013. He is currently a member of the board of directors of McKesson Corporation, vice-chair of the board of trustees for Johns Hopkins University, and a member of the board of trustees for Johns Hopkins Medicine. Dr Coles is also a member of the board of the US Olympic and Paralympic Foundation.
You may also be interested in...
Finding Value Left On The Shelf: Karuna Case Study
PureTech’s gamble to take an older Eli Lilly drug off the shelf to redevelop in a new indication paid off. The company aims to replicate this 'Karuna model' in the near future.
Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease
Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity.
Deals Of The Year 2023 Winners Revealed
For In Vivo's 16th annual Deals of the Year contest, we selected 12 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.